Unknown PHASE2 INTERVENTIONAL 2-arm NCT01843829

A Feasibility Study of Chemo-radiotherapy to Treat Operable Oesophageal Cancer (NeoSCOPE)

A Randomised Phase II Study of Two Pre-operative Chemoradiotherapy Regimens (Oxaliplatin and Capecitabine Followed by Radiotherapy With Either Oxaliplatin and Capecitabine or Paclitaxel and Carboplatin) for Resectable Oesophageal Cancer

Sponsor: Cancer Research UK

Conditions Oesophageal Cancer

Interventions Capecitabine Carboplatin Oxaliplatin Paclitaxel Radiotherapy Surgery

Updated 5 times since 2017 Last updated: Mar 21, 2014 Started: Oct 31, 2013 Primary completion: May 31, 2015 Completion: May 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01843829, this PHASE2 trial focuses on Oesophageal Cancer and remains ongoing. Sponsored by Cancer Research UK, it has been updated 5 times since 2013, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

First recorded

Oct 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cancer Research UK
Lisette Nixon

Data source: Velindre NHS Trust

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bristol, United Kingdom , Cardiff, United Kingdom , Coventry, United Kingdom , Derby, United Kingdom , Leeds, United Kingdom , Leicester, United Kingdom , London, United Kingdom , Manchester, United Kingdom , Oxford, United Kingdom , Sheffield, United Kingdom and 2 more locations